Overview

A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors

Status:
NOT_YET_RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
SoGreat is an open-label, single-arm, modular, two-stage, Phase Ib/II study. SoGreat (Part 1) is an open-label, modular, Phase Ib study.
Phase:
PHASE1
Details
Lead Sponsor:
Hunan Cancer Hospital
Collaborator:
Gilead Sciences
Treatments:
Anastrozole
exemestane
Fulvestrant
sacituzumab govitecan